124 related articles for article (PubMed ID: 27086733)
1. Prospective evaluation of the safety of compounded bulk material L-asparaginase in dogs with lymphoma.
Thiman J; Northrup N; Saba C; Clarke D; Regan R; Hamilton T; Lindell H; Hofmeister E
J Vet Pharmacol Ther; 2016 Dec; 39(6):572-577. PubMed ID: 27086733
[TBL] [Abstract][Full Text] [Related]
2. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
5. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
MacEwen EG; Rosenthal R; Matus R; Viau AT; Abuchowski A
Cancer; 1987 Jun; 59(12):2011-5. PubMed ID: 3567863
[TBL] [Abstract][Full Text] [Related]
6. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D
Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934
[TBL] [Abstract][Full Text] [Related]
7. Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
Speas AL; Lyles SE; Wirth KA; Fahey CE; Kow K; Lejeune AT; Milner RJ
J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):130-139. PubMed ID: 29469204
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
11. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
[TBL] [Abstract][Full Text] [Related]
12. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
Northrup NC; Rassnick KM; Snyder LA; Stone MS; Kristal O; Cotter SM; Moore AS
J Vet Intern Med; 2002; 16(5):570-5. PubMed ID: 12322708
[TBL] [Abstract][Full Text] [Related]
13. Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma.
Rogers KS; Barton CL; Benson PA; Green RA
Am J Vet Res; 1992 Apr; 53(4):580-4. PubMed ID: 1586032
[TBL] [Abstract][Full Text] [Related]
14. Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma.
Sayag D; Chamel G; Bédard C; Beauchamp G; Couturier S; Ponce F; Rannou B
Vet Clin Pathol; 2020 Sep; 49(3):476-483. PubMed ID: 32955128
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.
Blake MK; Carr BJ; Mauldin GE
Can Vet J; 2016 Feb; 57(2):176-82. PubMed ID: 26834270
[TBL] [Abstract][Full Text] [Related]
16. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Teske E; Rutteman GR; van Heerde P; Misdorp W
Eur J Cancer; 1990; 26(8):891-5. PubMed ID: 2145933
[TBL] [Abstract][Full Text] [Related]
17. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
MacDonald VS; Thamm DH; Kurzman ID; Turek MM; Vail DM
J Vet Intern Med; 2005; 19(5):732-6. PubMed ID: 16231719
[TBL] [Abstract][Full Text] [Related]
18. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.
Vail DM; Michels GM; Khanna C; Selting KA; London CA;
Vet Comp Oncol; 2010 Mar; 8(1):28-37. PubMed ID: 20230579
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and adverse events of continuous l-asparaginase administration for canine large cell lymphoma of presumed gastrointestinal origin.
Nakagawa T; Kojima M; Ohno K; Chambers JK; Uchida K; Ohmi A; Goto-Koshino Y; Tomiyasu H; Tsujimoto H
Vet Comp Oncol; 2022 Mar; 20(1):102-108. PubMed ID: 34213084
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase and MOPP treatment of dogs with lymphoma.
Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
